Clinuvel PharmaceuticalsASX:CUV +2.51%85 EBITDA Margin % is 47.75% as of Dec. 2025, which is 17% below its 10-year median of 57.80. GuruFocus rates ASX:CUV with a GF Score™ of 85/100 and a GF Value™ of A$17.70 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, Clinuvel Pharmaceuticals ranks better than 94.6% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Clinuvel Pharmaceuticals EBITDA Margin % Related Terms
Clinuvel Pharmaceuticals EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CUV vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinuvel Pharmaceuticals (ASX:CUV) has a EBITDA Margin % of 47.75% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Clinuvel Pharmaceuticals and its competitors. This is 17% below median its historical median of 57.80. According to the industry distribution chart, Clinuvel Pharmaceuticals ranks #51 out of 945 companies in the Biotechnology industry, placing it in the top 5.4%.
Is Clinuvel Pharmaceuticals' EBITDA Margin % too high?
Clinuvel Pharmaceuticals' current EBITDA Margin % of 47.75% is 17% below median its 10-year median of 57.80. Based on the distribution chart, Clinuvel Pharmaceuticals ranks #51 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clinuvel Pharmaceuticals ranks #51 out of 945 companies for EBITDA Margin %. This places Clinuvel Pharmaceuticals in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Clinuvel Pharmaceuticals and its competitors. Clinuvel Pharmaceuticals's current EBITDA Margin % is 47.75%, which is 17% below median its own 10-year median of 57.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (ASX:CUV) is currently considered Significantly Undervalued. The stock's GF Value™ is A$17.70, compared to a current price of A$10.20 — trading 42.4% below its estimated fair value. The current EBITDA Margin % is 47.75%, which is 17% below median its 10-year median of 57.80. Clinuvel Pharmaceuticals' overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (ASX:CUV), the current EBITDA Margin % is 47.75% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinuvel Pharmaceuticals (ASX:CUV) Overvalued in 2026?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued.
The current stock price of A$10.20 is trading 42.4% below its estimated GF Value™ of A$17.70.
GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for ASX:CUV:
EBITDA Margin %: 47.75% (17% below median its 10-year median of 57.80)
GF Value™: A$17.70 vs. price of A$10.20 (42.4% below fair value)
No single metric tells the full story. See the ASX:CUV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
85GF Score
Get the complete analysis for ASX:CUV
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CUV has been successfully added to your 
